Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.37 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.36 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.36 |
| ▸ | IKBKB | O14920 | 1/20 | 0.36 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA7 | P43166 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | TERT | O14746 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL769070 | 0.81 | MAOB (0.42) | NOTUMMAPTSRD5A1CYP19A1CA1 | |
| SCHEMBL5539707 | 0.78 | KDM4E (0.38) | NOTUMKDM4EMAPTHSD17B10CASP1 | |
| SCHEMBL9780105 | 0.76 | TSHR (0.40) | KDM4EMAPTHSD17B10CASP1CASP7 | |
| SCHEMBL8790746 | 0.76 | ADORA2A (0.38) | KDM4EMAPTHSD17B10CASP1CASP7 | |
| SCHEMBL10158539 | 0.76 | MAPT (0.42) | KDM4EMAPTHSD17B10CASP1CASP7 | |
| SCHEMBL17397682 | 0.76 | KDM4E (0.37) | NOTUMKDM4EMAPTHSD17B10CASP1 | |
| SCHEMBL1137861 | 0.76 | MAPT (0.47) | KDM4EMAPTHSD17B10CASP1CASP7 | |
| SCHEMBL855947 | 0.73 | MAOB (0.47) | NOTUMKDM4EMAPTHSD17B10PDE3B | |
| SCHEMBL21236396 | 0.73 | USP8 (0.36) | NOTUMKDM4EHSD17B10GAAMEN1 | |
| SCHEMBL1266056 | 0.73 | NOTUM (0.44) | NOTUMMAPTHSD17B10CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | MEDSHINE DISCOVERY INC. (CN) | 2023-11-02 | — | — | US | disclosed |
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | MEDSHINE DISCOVERY INC. (CN) | 2023-11-02 | — | — | US | disclosed |
| WO-2021047674-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | 南京明德新药研发有限公司 | 2021-03-18 | — | — | WO | disclosed |
| EP-3312184-A1 | PIPERIDINE DERIVATIVE AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | Jiangsu Hengrui Medicine Co., Ltd. (CN) | 2018-04-25 | — | — | EP | disclosed |
| WO-2016202161-A1 | PIPERIDINE DERIVATIVE AND PREPARATION METHOD AND PHARMACEUTICAL USE THEREOF | 江苏恒瑞医药股份有限公司 | 2016-12-22 | — | — | WO | disclosed |
| US-7884109-B2 | immunosuppressants such as 2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-((1R,4R)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)-7H-purin-8(9H)-one, used for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection | WYETH LLC (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884109-B2 | immunosuppressants such as 2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-((1R,4R)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)-7H-purin-8(9H)-one, used for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection | WYETH LLC (US) | 2011-02-08 | — | — | US | disclosed |
| US-7884109-B2 | immunosuppressants such as 2-(6-Fluoro-1H-benzo[d]imidazol-1-yl)-9-((1R,4R)-4-hydroxy-1,2,3,4-tetrahydronaphthalen-1-yl)-7H-purin-8(9H)-one, used for the prevention and treatment of autoimmune diseases, inflammatory disease, mast cell mediated disease and transplant rejection | WYETH LLC (US) | 2011-02-08 | — | — | US | disclosed |
| EP-2099800-A1 | 7-SUBSTITUTED PURINE DERIVATIVES FOR IMMUNOSUPPRESSION | Pharmacopeia, LLC (US) | 2009-09-16 | — | — | EP | disclosed |
| US-20080287468-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2008-11-20 | — | — | US | disclosed |
| WO-2008060301-A1 | 7-SUBSTITUTED PURINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA , LLC (US) | 2008-05-22 | — | — | WO | disclosed |
| US-20080119496-A1 | 7-Substituted Purine Derivatives for Immunosuppression | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119496-A1 | 7-Substituted Purine Derivatives for Immunosuppression | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119496-A1 | 7-Substituted Purine Derivatives for Immunosuppression | PHARMACOPEIA DRUG DISCOVERY, INC. (US) | 2008-05-22 | — | — | US | disclosed |
| WO-2008060301-A1 | 7-SUBSTITUTED PURINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA , LLC (US) | 2008-05-22 | — | — | WO | disclosed |
| EP-1874772-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2008-01-09 | — | — | EP | disclosed |
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | WYETH LLC | 2007-01-25 | — | — | US | disclosed |
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | WYETH LLC | 2007-01-25 | — | — | US | disclosed |
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | WYETH LLC | 2007-01-25 | — | — | US | disclosed |
| WO-2006108103-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | PHARMACOPEIA, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119496-A1 | 7-Substituted Purine Derivatives for Immunosuppression | P2RX7, P2RX5, P2RY1 | NOTUM 4102/4885KDM4E 878/4885MAPT 4695/4885 |
| US-20230348441-A1 | BICYCLIC COMPOUND THAT ACTS AS CRBN PROTEIN REGULATOR | CRBN, CRKL, NCOR1 | NOTUM 4711/4885KDM4E 2887/4885MAPT 2404/4885 |
| US-20070021443-A1 | Purine and imidazopyridine derivatives for immunosuppression | TPMT, P2RY4, P2RY1 | NOTUM 3348/4885KDM4E 1491/4885MAPT 4620/4885 |
| US-20080287468-A1 | PURINE AND IMIDAZOPYRIDINE DERIVATIVES FOR IMMUNOSUPPRESSION | TPMT, P2RY4, P2RY1 | NOTUM 3348/4885KDM4E 1491/4885MAPT 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.